Understanding Mechanisms of Histone Deacetylase Inhibitors in Regulating Growth and Survival in Aggressive Diffuse Large B-Cell Lymphoma
PublisherThe University of Arizona.
RightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
AbstractDiffuse large B-cell lymphoma (DLBCL) is an aggressive and commonly-diagnosed form of non-Hodgkin lymphoma. Under the current standard of treatment, R-CHOP, 40% of patients are refractory or relapse, and need further therapeutic intervention. Histone deacetylases (HDACs) have a large role in cancer cell survival and can be targeted therapeutically for cancer treatment with combination treatments. However, efficient use of HDACi in combination treatments is hindered by a poor understanding of their mechanisms of action. To address this, we developed a pre-clinical model system of sensitivity and resistance to the Class I and Class IIb pan-HDACi, belinostat, using DLBCL cell lines. Cell lines sensitive to belinostat undergo mitotic arrest, followed by apoptosis. Cells resistant to belinostat arrest in G1. Forced mitotic arrest in HDACi-resistant cell lines with a microtubule targeting agent, vincristine, in combination with belinostat caused synergistic cytotoxicity associated with downregulated expression of anti-apoptotic factor MCL-1 and upregulated pro-apoptotic factor BIM. Vincristine-induced cellular polyploidy was also eliminated by belinostat. Additionally, inhibition of just Class I HDACs is sufficient for synergistic apoptosis with vincristine, and reduces polyploidy. Our results suggest that all class I HDAC-containing complexes must be targeted to observe maximal cytotoxicity in combination with vincristine in resistant cell lines.
Degree ProgramHonors College
Molecular & Cellular Biology